Eric Joseph Rubin, M.D., Ph.D.
This page shows the publications co-authored by Eric Rubin and Ravikiran Raju.
Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease. Emerg Infect Dis. 2016 Mar; 22(3):365-9.
Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis. PLoS Pathog. 2014 Mar; 10(3):e1003994.
Bacterial proteolytic complexes as therapeutic targets. Nat Rev Drug Discov. 2012 Oct; 11(10):777-89.
Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog. 2012 Feb; 8(2):e1002511.
Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat Med. 2016 05; 22(5):531-8.
An Antibacterial ß-Lactone Kills Mycobacterium tuberculosis by Disrupting Mycolic Acid Biosynthesis. Angew Chem Int Ed Engl. 2018 01 02; 57(1):348-353.
Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. mBio. 2015 May 05; 6(3):e00253-15.
The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring. EMBO J. 2012 Mar 21; 31(6):1529-41.
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2012 Jan; 56(1):324-31.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.